Table 4.
Evolution of endogenous vasoactive substances before and after standard medical therapy (SMT) alone or treatment with the molecular adsorbent recirculating system (MARS)/Prometheus devices combined with SMT
| SMT | MARS + SMT | Prometheus + SMT | ||||
| Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
| Plasma renin activity (μg/l/hour) | 9.8 ± 3.0 | 10.8 ± 3.4 | 12.6 ± 3.9 | 5.5 ± 2.3* | 10.7 ± 3.4 | 12.4 ± 4.2 |
| Aldosterone (ng/l) | 417.4 ± 102.1 | 483 ± 124.9 | 460.5 ± 123.2 | 137.5 ± 30.2* | 394.4 ± 176.7 | 433.3 ± 235.4 |
| Norepinephrine (μg/l) | 0.90 ± 0.24 | 1.36 ± 0.47 | 0.82 ± 0.19 | 0.46 ± 0.07* | 1.28 ± 0.43 | 1.31 ± 0.40 |
| Vasopressin (pg/ml) | 10.8 ± 1.7 | 10.2 ± 1.5 | 8.9 ± 0.6 | 6.5 ± 0.7** | 9.4 ± 1.4 | 9.4 ± 1.3 |
| Nitrate/nitrite (μM) | 68.6 ± 9.9 | 74.7 ± 13.1 | 91.2 ± 16.1 | 40.4 ± 5.9* | 73.6 ± 14.4 | 84.4 ± 17.6 |
P value versus start of the study period: *P < 0.05, **P ≤ 0.005.